Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes.
BACKGROUND
CD52 monoclonal antibody (mAb) has been used therapeutically in lymphocytic leukemia, autoimmune disease, and organ transplantation. But the effect of CD52 mAb on intestinal intraepithelial lymphocytes (IELs) was unknown. The aim of this study was to assess the influence of anti-mouse CD52 mAb on IELs.


METHODS
Twenty male C57BL/6 mice were randomly assigned to a treatment or a control group. The treatment group received anti-mouse CD52 mAb (20 mug, subcutaneously), whereas the control group received the same volume of phosphate-buffered solution. On the seventh day after treatment, mice were killed, and ileum and colon were obtained for histopathology and immunohistochemistry examination, IELs were isolated for flow cytometric analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis. Furthermore, the intestinal permeability was measured by lactulose-mannitol test.


RESULTS
The number and viability of IELs were decreased significantly in treatment compared with the control group. There were significant differences between the two groups considering IELs phenotypes. In addition, the proportion of apoptotic IELs in CD52 mAb treatment group was significantly higher than the control group (19.59%+/-3.13% and 2.02%+/-0.33%, respectively; P<0.05). Furthermore, lactulose-mannitol test showed a marked increase intestinal permeability after CD52 treatment (90.38%+/-5.96% and 46.02%+/-6.40%, respectively; P<0.05).


CONCLUSIONS
Anti-mouse CD52 mAb could induce more IELs to apoptosis and result in reducing the number of IELs, which may disrupt intestinal barrier function.
Qu
Linlin
L
School of Medicine, Nanjing University, Nanjing, People's Republic of China.
Li
Qiurong
Q
Jiang
Haitao
H
Gu
Lili
L
Zhang
Qiang
Q
Wang
Chenyang
C
Li
Jieshou
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D017209:Apoptosis / Q000276:immunology; D000074301:CD52 Antigen; D002470:Cell Survival / Q000276:immunology; D004848:Epithelium / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D018928:Immunity, Mucosal; D007279:Injections, Subcutaneous; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000276:immunology* / Q000473:pathology*; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion / Q000009:adverse effects; D008214:Lymphocytes / Q000276:immunology* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010539:Permeability; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; D006023:Glycoproteins